Analysis
What Tirzepatide Actually Costs at a Maintenance Dose: Five Ladders, Compared
Five providers publish what happens when the dose rises, and every one of them charges more. The steepest published ladder runs $399 to $524, a 31% increase from starter
Five providers publish what happens when the dose rises, and every one of them charges more. The steepest published ladder runs $399 to $524, a 31% increase from starter to maintenance. One programme we captured is flat at $186 across the full range. Ranked on the advertised figure, the flat programme looks mid-table; ranked on the maintenance figure it is the cheapest.
What does each published ladder actually do?
The advertised price is almost always the starting dose. Labelling directs increases every four weeks to a maintenance dose of 10 or 15 mg over roughly 20 to 24 weeks, and states 2.5 mg is treatment initiation and is not approved as a maintenance dosage. So the figure most comparison tables rank on is a figure that stops applying in month two.
| Programme | Advertised | At maintenance | Change | Evidence |
|---|---|---|---|---|
| Flat, 12-month | $186 | $186 | 0% | Captured at source |
| Flat, month-to-month | $215 | $215 | 0% | Captured at source |
| Medication plus membership | $199 | $278 | +40% | Captured at source |
| Intro month then ongoing | $199 | $299 | +50% | Reported, provider-published |
| Intro month then ongoing (2) | $349 | $449 | +29% | Reported |
| Dose-tiered | $399 | $449 | +13% | Reported |
| Dose-tiered, steepest | $399 | $524 | +31% | Reported |
| Brand vials, by dose | $299 | $449 | +50% | Captured at source |
Reported rows come from a competitor's published comparison, which attributes each figure to a third-party review. We record them as reported rather than captured because we have not read them on the provider's own page. Not one published ladder goes down.
Every provider that publishes a dose ladder charges more at the top of it. The steepest runs +31% from starter to maintenance; the brand's own vial channel runs +50%.
Ranked on the advertised figure, a flat $186 programme sits mid-table behind three cheaper-looking headlines. Ranked on the maintenance figure — the one you actually pay from about month five — it is the cheapest on this page by a margin of $92 to $338 a month.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What does that do to a year?
| Programme | Advertised | Twelve months | Against the flat plan |
|---|---|---|---|
| Flat, 12-month | $186 | $2,232 | — |
| Medication plus membership | $199 | $3,336 | +$1,104 |
| Intro then $299 ongoing | $199 | ~$3,488 | +$1,256 |
| Intro then $449 ongoing | $349 | ~$5,288 | +$3,056 |
| Dose-tiered to $524 | $399 | ~$5,900 | +$3,668 |
The programme advertising $13 less than the flat plan costs $1,104 more over the year. The one advertising $213 more costs $3,668 more.
Which structures are honest about it?
This is worth separating from the arithmetic, because the two are not the same thing.
- A flat rate stated on the provider's own page is the clearest structure: the advertised figure is the maintenance figure.
- “$199 first month, then $299 all doses” is an intro rate, and a provider printing both numbers in the same sentence has disclosed it properly. The ongoing figure is the one to compare.
- A published dose ladder — $399, then $499, then $524 — is also honest disclosure. It is more expensive and more transparent than a single teaser figure.
- A medication price quoted without a mandatory membership is the structure that misleads most, because both numbers are accurate and only one is what you pay.
We rank on the maintenance figure. We do not treat disclosure as a penalty, and a provider that publishes its ladder is doing something the ones with a single unexplained headline are not.
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $215 | $195 | $190 | $186 | $2,232 |
| Microdose | $189 | $159 | $150 | $147 | $1,764 |
| Sublingual ODT | $229 | $219 | $205 | $199 | $2,388 |
Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
What should I ask?
- What will I pay per month at 10 mg, on the plan I would sign? One number means flat. A range means a ladder, and the top of the range is your real cost.
- Is that in writing? A landing page can change tomorrow; an email cannot.
- Is anything billed separately? Membership, consultation, labs, shipping, dose-increase surcharges.
- Is the first month a promotional rate? If so, what is the ongoing figure?
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Does compounded tirzepatide cost more at higher doses?
On every published ladder we can find, yes. The steepest runs from $399 at the starter dose to $524 at 15 mg, a 31% increase. One programme we captured is flat at $186 across the full range.
What is the cheapest tirzepatide at a maintenance dose?
The lowest maintenance figure we have read at source is $186 a month flat, $2,232 over twelve months. Programmes advertising less than that cost between $1,104 and $3,668 more over a year.
Why do comparison tables rank on the starter price?
Because it is the advertised figure. Labelling calls the starting dose treatment initiation rather than a maintenance dosage, so it applies for roughly one month of an indefinite treatment.
Is a published dose ladder a bad sign?
No. A provider printing $399, $499 and $524 has disclosed its structure properly. It is more expensive and more transparent than a single unexplained headline figure.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Cheapest Compounded Tirzepatide: Ongoing Costs ComparedPillar / Money
- Compounded Tirzepatide Online: Legal, Safety and Cost GuidePillar / Money
- Mochi Health vs Henry MedsComparisons
- How Dose Escalation Changes Tirzepatide CostJournal
- Tirzepatide Price by DosePillar / Money
- Flat-Rate vs Dose-Escalating GLP-1 PricingComparisons
- Flat-Rate Tirzepatide Pricing ComparedPillar / Money
Related coverage
GLP-1 Tirzepatide Rank. “What Tirzepatide Actually Costs at a Maintenance Dose: Five Ladders, Compared.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-price-escalation-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.